Avidity Biosciences (RNA) to Release Quarterly Earnings on Thursday

Avidity Biosciences (NASDAQ:RNA) is projected to release its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect Avidity Biosciences to post earnings of ($1.05) per share and revenue of $2.00 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Avidity Biosciences (NASDAQ:RNA) last released its quarterly earnings data on Monday, February 23rd. The biotechnology company reported ($1.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.35). The firm had revenue of $0.86 million for the quarter, compared to the consensus estimate of $1.98 million. Avidity Biosciences had a negative net margin of 3,650.39% and a negative return on equity of 44.92%. On average, analysts expect Avidity Biosciences to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Avidity Biosciences Stock Performance

NASDAQ:RNA opened at $13.09 on Thursday. Avidity Biosciences has a fifty-two week low of $11.95 and a fifty-two week high of $16.77. The firm has a 50-day simple moving average of $17.32 and a two-hundred day simple moving average of $51.62.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on RNA. Wells Fargo & Company began coverage on shares of Avidity Biosciences in a research note on Wednesday, March 11th. They set an “overweight” rating for the company. HC Wainwright restated a “neutral” rating on shares of Avidity Biosciences in a research note on Friday, May 1st. Wall Street Zen upgraded shares of Avidity Biosciences to a “hold” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Avidity Biosciences in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $69.42.

Institutional Trading of Avidity Biosciences

A number of institutional investors have recently made changes to their positions in RNA. Pentwater Capital Management LP boosted its holdings in shares of Avidity Biosciences by 30,032.5% during the 4th quarter. Pentwater Capital Management LP now owns 6,026,500 shares of the biotechnology company’s stock valued at $434,691,000 after acquiring an additional 6,006,500 shares during the last quarter. HBK Investments L P purchased a new stake in shares of Avidity Biosciences during the 4th quarter valued at about $314,847,000. Bellevue Group AG purchased a new stake in shares of Avidity Biosciences during the 3rd quarter valued at about $93,800,000. TIG Advisors LLC purchased a new stake in shares of Avidity Biosciences during the 4th quarter valued at about $129,955,000. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in shares of Avidity Biosciences by 119.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,630,966 shares of the biotechnology company’s stock valued at $189,772,000 after acquiring an additional 1,430,966 shares during the last quarter.

About Avidity Biosciences

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.